Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) has issued a profit forecast, expecting a net profit of 1.43 billion yuan for the year 2024, an increase of 121.99% year-on-year.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company expects to achieve a net profit attributable to the owners of the parent company of 1.43 billion yuan in 2024, a year-on-year increase of 121.99%. The main reasons for the performance growth are: The company's core product, Fumitelanib mesylate tablets, was renewed and included in the national medical insurance catalog, leading to continuous growth in sales revenue. At the same time, the company has effectively implemented a number of cost reduction and efficiency improvement measures, strict control over various costs and expenses, resulting in a significant improvement in the company's performance.